EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2007-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2007.070367PMID 17504841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

  2010cited by this paper
• Competing interests: none declared.

  2006cited by this paper
• The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial

  2006cited by this paper
• Anti-inflammatory and immunosuppressive drugs and reproduction

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials.

  2006cited by this paper
• Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis.

  2006cited by this paper
• Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.

  2006cited by this paper
• Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus

  2005cited by this paper
• The long-term prognosis of renal transplantation in patients with lupus nephritis.

  2005cited by this paper
• In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: comment on the article by Sfikakis et al.

  2005cited by this paper
• Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.

  2005cited by this paper
• An international cohort study of cancer in systemic lupus erythematosus.

  2005cited by this paper
• Lupus nephritis flares

  2005cited by this paper
• Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients

  2005cited by this paper
• Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.

  2005cited by this paper
• Long-term Survival of Southern Chinese Patients With Systemic Lupus Erythematosus: A Prospective Study of All Age-Groups

  2005cited by this paper
• Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

  2005cited by this paper
• A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1

  2005cited by this paper
• Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

  2005cited by this paper
• Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

  2005cited by this paper
• B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

  2005cited by this paper
• Combined oral contraceptives in women with systemic lupus erythematosus.

  2005cited by this paper
• Lupus thrombocytopenia: clinical implications and prognostic significance

  2005cited by this paper
• Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.

  2005cited by this paper
• Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

  2005cited by this paper
• Prolonged remission in systemic lupus erythematosus.

  2005cited by this paper
• Methotrexate in systemic lupus erythematosus

  2005cited by this paper
• A trial of contraceptive methods in women with systemic lupus erythematosus.

  2005cited by this paper
• Urinary tract infections and lupus erythematosus

  2004cited by this paper
• EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees

  2004cited by this paper
• Treatment for lupus nephritis.

  2004cited by this paper
• Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials.

  2004cited by this paper
• Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus

  2004cited by this paper
• Undiagnosed Systemic Lupus Erythematosus in a Cohort of Infertile Women

  2004cited by this paper
• Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center.

  2004cited by this paper
• The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial

  2004cited by this paper
• Epileptic seizures in systemic lupus erythematosus

  2004cited by this paper
• Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.

  2004cited by this paper
• Sequential therapies for proliferative lupus nephritis.

  2004cited by this paper
• A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth.

  2004cited by this paper
• Clinical trial design in systemic lupus erythematosus: lessons learned and future directions

  2004cited by this paper
• Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance

  2004cited by this paper
• Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.

  2004cited by this paper
• Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.

  2004cited by this paper
• Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95.

  2004cited by this paper
• High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.

  2004cited by this paper
• Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort.

  2004cited by this paper
• Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone

  2003cited by this paper
• Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)

  2003cited by this paper
• A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.

  2003cited by this paper
• Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients

  2003cited by this paper
• The risk of pregnancy in patients with lupus nephritis.

  2003cited by this paper
• Outcome of renal transplantation in patients with systemic lupus erythematosus

  2003cited by this paper
• Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study.

  2003cited by this paper
• Premature coronary-artery atherosclerosis in systemic lupus erythematosus.

  2003cited by this paper
• Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis

  2003cited by this paper
• Survival of recipients of cadaveric kidney transplants compared with those receiving dialysis treatment in Australia and New Zealand, 1991-2001.

  2002cited by this paper
• Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.

  2002cited by this paper
• Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus

  2002cited by this paper
• Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies.

  2002cited by this paper
• Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians.

  2002cited by this paper
• Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus

  2002cited by this paper
• Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy.

  2002cited by this paper
• Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.

  2002cited by this paper
• Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort

  2001cited by this paper
• A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.

  2001cited by this paper
• Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.

  2001cited by this paper
• Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations.

  2001cited by this paper
• Pregnancy outcomes in women with systemic lupus erythematosus

  2001cited by this paper
• Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus

  2001cited by this paper
• Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

  2001cited by this paper
• Skin lesions - an indicator of disease activity in systemic lupus erythematosus?

  2001cited by this paper
• Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus.

  2001cited by this paper
• Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.

  2001cited by this paper
• Management of thrombosis in antiphospholipid antibody syndrome.

  2001cited by this paper
• OUTCOME AFTER TRANSPLANTATION OF YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A REPORT OF THE NORTH AMERICAN PEDIATRIC RENAL TRANSPLANT COOPERATIVE STUDY

  2001cited by this paper
• Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis

  2001cited by this paper
• Risk Factors Associated with Fetal Losses in Treated Antiphospholipid Syndrome Pregnancies: A Multivariate Analysis

  2001cited by this paper
• Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual.

  2001cited by this paper
• Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test

  2000cited by this paper
• Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations

  2000cited by this paper
• [Antiphospholipid syndrome(APS)].

  2000cited by this paper
• Cognitive impairment in systemic lupus erythematosus: a follow-up study

  2000cited by this paper
• Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group.

  2000cited by this paper
• Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity.

  2000cited by this paper
• Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.

  2000cited by this paper
• Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

  2000cited by this paper
• Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus.

  2000cited by this paper
• Hopkins Lupus Cohort. 1999 update.

  2000cited by this paper
• Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study.

  2000influential reference
• Prognostic parameters for flare in systemic lupus erythematosus.

  2000cited by this paper
• Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis.

  2000cited by this paper
• COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT

  2000cited by this paper
• Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis

  2000cited by this paper
• Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls

  2000cited by this paper
• Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.

  2000cited by this paper
• A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population.

  2000cited by this paper
• Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus.

  1999cited by this paper
• Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.

  1999cited by this paper

• Systemic Lupus Erythematosus-Associated Myelitis Mimicking Spinal Glioblastoma: A Case Report.

  2026cites this paper
• EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus.

  2025cites this paper
• Utilisation patterns of immunomodulators and pregnancy outcomes in systemic lupus erythematosus: Insights from Korean national data

  2025cites this paper
• Efficacy of Belimumab on Different Joint and Skin Manifestations of Systemic Lupus Erythematosus: Real-Life Data from a New Multicentric, Nationwide Italian Cohort (BeRLiSS-JS 2.0)

  2025cites this paper
• Neurological Manifestations of Systemic Lupus Erythematosus: A Comprehensive Review

  2025cites this paper
• Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden.

  2025cites this paper
• Analysis of the causal association between systemic lupus erythematosus and osteonecrosis: A bidirectional 2-sample Mendelian randomization study

  2025cites this paper
• Recurrent lower motor neuron type facial palsy: an unusual manifestation of SLE

  2025cites this paper
• Fragmented care in lupus: Patient experiences and insights

  2025cites this paper
• A Review on the Treatment and Diagnosis of Systemic Lupus Erythematosus Using Nanoparticle Systems

  2025cites this paper
• Acute stroke as the initial manifestation of neuropsychiatric lupus erythematosus and anti-phospholipid syndrome in a child patient

  2025cites this paper
• Systemic lupus erythematosus masquerading as childhood onset treatment-resistant depressive disorder - A case report.

  2025cites this paper
• A case–control study on autoimmune polyendocrine syndromes in patients with systemic lupus erythematosus

  2025cites this paper
• Physical fitness and physical activity of a quadriplegic amputee patient with systemic lupus erythematosus (SLE) – a case study

  2025cites this paper
• Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply.

  2025cites this paper
• LADA diabetes as an orphan disease and its connection with other autoimmune diseases

  2024cites this paper
• Association between hydroxychloroquine use and risk of diabetes mellitus in systemic lupus erythematosus and rheumatoid arthritis: a UK Biobank-based study

  2024cites this paper
• Development of quality indicators for pregnancy and childbirth in patients with systemic lupus erythematosus.

  2024cites this paper
• Interpersonal Communication Patterns of Lupus Patients at Cinta Kupu Community

  2024cites this paper
• Analysis of belimumab prescription and outcomes in a 10-year monocentric cohort: is there an advantage with early use?

  2024cites this paper
• Current Pathogenesis and Treatment of Autoimmune Diseases

  2024cites this paper
• Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus

  2024cites this paper
• Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort.

  2024cites this paper
• Clinical association of FKBP5 gene in systemic lupus erythematosus patients

  2024cites this paper
• B-cell depletion in autoimmune diseases

  2024cites this paper
• Disease activity at the onset of diagnosis as a predictor of disease outcomes in a cohort of patients with systemic lupus erythematosus: A post hoc retrospective analysis of the COMOSLE-EGYPT study

  2024cites this paper
• Screening for Asymptomatic Osteonecrosis of the Hip in Systemic Lupus Erythematous: A Systematic Review and Meta-Analysis of MRI-Based Prevalence

  2024cites this paper
• Cardiac Tamponade and Primary Biliary Cholangitis: An Unusual Presentation and a Rare Association of Systemic Lupus Erythematosus

  2024cites this paper
• Domain 5 of Beta 2 glycoprotein I: Friend or foe in health? Context matters.

  2024cites this paper
• Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage

  2024cites this paper
• Evaluating GCS and FOUR Score in Predicting Mortality of Traumatic Brain Injury Patients (TBI): A Prospective Study in a Tertiary Hospital of South Malabar

  2024cites this paper
• Clinical Practice Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus: 2024 Update.

  2024cites this paper
• Die 2023 EULAR-Empfehlungen zur Behandlung des systemischen Lupus erythematodes – Implikationen für die Versorgung in Deutschland

  2024cites this paper
• Guías de Práctica Clínica para el tratamiento del lupus eritematoso sistémico del Colegio Mexicano de Reumatología. Actualización 2024

  2024cites this paper
• Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus

  2024cites this paper
• Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review

  2024cites this paper
• Accumulation of Fat Not Responsible for Femoral Head Necrosis, Revealed by Single-Cell RNA Sequencing: A Preliminary Study

  2023cites this paper
• Determinants of Low Disease Activity And Remission in Pediatric Systemic Lupus Erythematosus Patients

  2023cites this paper
• Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study

  2023cites this paper
• EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

  2023cites this paper
• CAR T Cell Therapy: A New Hope for Refractory Lupus?

  2023cites this paper
• Psychosis Caused by a Somatic Condition: How to Make the Diagnosis? A Systematic Literature Review

  2023cites this paper
• Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy

  2023cites this paper
• Concurrent occurrence of acute pancreatitis and intracerebral hemorrhage as presenting manifestations in lupus: a case report

  2023cites this paper
• An Osteopathic Approach to the Management of Systemic Lupus Erythematosus

  2023cites this paper
• Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus

  2023cites this paper
• Anemia in Colombian patients with systemic lupus erythematosus

  2023cites this paper
• Antiphospholipid Syndrome: State of the Art of Clinical Management

  2023cites this paper
• A comparison of the chemiluminescence immunoassay and Crithidia luciliae immunofluorescence test in detecting anti-dsDNA antibodies and assessing the activity of systemic lupus erythematosus

  2023cites this paper
• Global, Regional, and National Prevalence of Gout From 1990 to 2019: Age-Period-Cohort Analysis With Future Burden Prediction

  2023cites this paper
• Health related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.

  2023cites this paper
• Egyptian recommendations for the management of systemic lupus erythematosus: a consensus, evidence-based, clinical practice guidelines for treat-to-target management

  2023cites this paper
• Cardiac Magnetic Resonance Imaging T1 and T2 Mapping in Systemic Lupus Erythematosus in Relation to Antimalarial Treatment

  2023cites this paper
• Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment–specific patient-reported outcome measure

  2023cites this paper
• Steroid-loaded reconstituted high-density lipoprotein nanocarrier: A new treatment for systemic lupus erythematosus

  2023cites this paper
• Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study

  2023cites this paper
• Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects

  2023cites this paper
• Systemic Lupus Erythematosus in a Patient with Liver Cirrhosis: Case Report and Literature Review

  2023cites this paper
• Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial

  2022cites this paper
• Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis

  2022cites this paper
• Pregnancy in lupus: an updated consensus to guide best practice strategies

  2022cites this paper
• Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases

  2022cites this paper
• Recommendations for Systemic Lupus Erythematosus: Balancing Evidence and Eminence to Facilitate the Medical Care of a Complex Disease.

  2022cites this paper
• Prolonged Fever, Travel, and the Changing Examination in an 8-year-old Girl.

  2022cites this paper
• Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies

  2022cites this paper
• The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

  2022cites this paper
• Systemic lupus erythematosus: overview, management and COVID-19.

  2022cites this paper
• Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients

  2022cites this paper
• Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.

  2022cites this paper
• Will New Treatment Options for Lupus Nephritis Be Affordable?

  2022cites this paper
• Glucocorticoid-free Treatment of Systemic Lupus Erythematosus: Is it Feasible?

  2022cites this paper
• Physical Activity and Systemic Lupus Erythematosus Among European Populations: A Two-Sample Mendelian Randomization Study

  2022cites this paper
• RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study

  2022cites this paper
• Buccofacial Manifestations of Systemic Lupus Erythematosus and Role of the Oral Surgeon in its Diagnosis and Management: Case Report and Review of the Literature

  2022cites this paper
• Association between systemic lupus erythematosus and cancer: findings from cohort studies and Mendelian randomization analysis

  2021cites this paper
• A prescription for exercise in systemic lupus erythematosus

  2021cites this paper
• Premature rupture of membranes – A cause of foetal complications among lupus: A cohort study, systematic review and meta-analysis

  2021cites this paper
• Systemic Lupus Erythematosus (SLE)

  2021cites this paper
• Diagnostic Validity of Lung Ultrasonogram in Comparison with High-Resolution Computed Tomography in Interstitial Lung Disease Associated with Connective Tissue Disease

  2021cites this paper
• Evaluation of hydroxychloroquine induced retinal toxicity in systemic lupus erythematosus patients

  2021influential citation
• A CASE WITH SYSTEMIC LUPUS ERITHEMATOSUS MIMICKING COVID-19 PNEUMONIA

  2021cites this paper
• Systematic review of anti-dsDNA testing for systemic lupus erythematosus: A meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay.

  2021cites this paper
• Systemic Lupus Erythematosus with neuropsychiatric manifestations in a child: case report and review of the international recommendations for the diagnostics and management

  2021cites this paper
• A study on echocardiographic findings in hospitalized patients with connective tissue diseases

  2021cites this paper
• Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement.

  2021cites this paper
• Risk factors for serious infections in inpatients with systemic lupus erythematosus.

  2021cites this paper
• Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients

  2021cites this paper
• Novel Therapeutic Interventions in Systemic Lupus Erythematosus

  2021cites this paper
• Autoimmune diseases in patients undergoing percutaneous coronary intervention: A risk factor for in-stent restenosis?

  2021cites this paper
• COVID-19 and pregnancy: the fruitful experience of the university hospital of Tangier Morocco with hydroxychloroquine and anti-retroviral treatment

  2021cites this paper
• Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome

  2021cites this paper
• Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.

  2021cites this paper
• Ischemic Stroke in the Young

  2021cites this paper
• The Impact of Serum Anti-neutrophil Cytoplasmic Antibody on Clinical Characteristics and Outcomes in Pediatric-Onset Systemic Lupus Erythematosus Patients

  2021cites this paper
• Self-Reported Symptoms in a Cohort of Rheumatoid Arthritis and Systemic Lupus Erythematosus during the COVID-19 Quarantine Period

  2021cites this paper
• The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.

  2021cites this paper
• Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases

  2021cites this paper
• Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort

  2021cites this paper
• Human Cytomegalovirus and Autoimmune Diseases: Where Are We?

  2021cites this paper
• Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

  2021cites this paper